Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 8/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047246 | 0.95 | CYP1A2 (0.54) | CYP1A2CYP11B1CYP11B2ALOX15TSHR | |
| SCHEMBL16090313 | 0.82 | CDC7 (0.67) | CYP1A2CYP11B1CYP11B2ALOX15CDC7 | |
| SCHEMBL16090326 | 0.81 | PGR (0.57) | CYP1A2CYP11B1CYP11B2CDC7CCNE1 | |
| SCHEMBL3132725 | 0.79 | PGR (0.73) | CYP1A2CYP11B1CYP11B2CDC7CCNE1 | |
| SCHEMBL5318114 | 0.79 | KDR (0.54) | FLT1KDR | |
| SCHEMBL77084 | 0.74 | ALOX15 (0.96) | CYP1A2ALOX15TSHRCASP1FLT1 | |
| SCHEMBL9238093 | 0.74 | ALOX15 (0.96) | CYP1A2ALOX15TSHRCASP1FLT1 | |
| SCHEMBL2684521 | 0.74 | ALOX15 (0.96) | CYP1A2ALOX15TSHRCASP1FLT1 | |
| SCHEMBL1267325 | 0.74 | ALOX15 (0.96) | CYP1A2ALOX15TSHRCASP1FLT1 | |
| SCHEMBL16049393 | 0.73 | CYP1A2 (0.55) | CYP1A2CYP11B1CYP11B2PGRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | CYP1A2 4725/4885CYP11B1 3919/4885CYP11B2 4281/4885 |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | CYP1A2 107/4885CYP11B1 67/4885CYP11B2 80/4885 |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | CYP1A2 107/4885CYP11B1 67/4885CYP11B2 80/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | CYP1A2 3650/4885CYP11B1 2681/4885CYP11B2 2874/4885 |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | CYP1A2 107/4885CYP11B1 67/4885CYP11B2 80/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | CYP1A2 1064/4885CYP11B1 1557/4885CYP11B2 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.